Research, development, production, and marketing of prescription drugs in four therapeutic areas: cardiovascular, renal & metabolism, oncology, respiratory & immunology, and rare diseases.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: January 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
AstraZeneca
B
Research and development of innovative pharmaceuticals in various therapeutic areas, including oncology, cardiovascular diseases, respiratory diseases, and immunology.
Servier
A
Development and marketing of pharmaceutical products, with a focus on cardiology, venous diseases, oncology, and neurology. Investment in R&D for innovative and targeted therapeutic solutions.
Chiesi
B
Development and delivery of innovative pharmaceutical products for respiratory, neonatology, transplantation, and rare diseases.
Initiatives identified among leaders
Réduction des émissions de gaz à effet de serre
“LES LABORATOIRES SERVIER INDUSTRIE réduit les émis...” - ServierSuivi d'indicateurs sociaux et de sécurité pour les employés et patients
“AstraZeneca mesure et publie des indicateurs socia...” - AstraZenecaInvestissement dans un outil de suivi énergétique avec sous-compteurs
“Chiesi SAS a investi dans un outil de pilotage des...” - Chiesi66% of similar organizations communicate on CSR issues
+968 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports